OSE Immunotherapeutics Sylvie Détry sylvie.detry@ose-immuno.com +33 153 198 757 Investor Relations Thomas Guillot thomas.guillot@ose-immuno.com +33 607 380 431 OSE Immunotherapeutics Provides Positive Long Term Memory Responses ... Presentations to focus on CLEC-1, novel myeloid immune checkpoint target for cancer immunotherapyNANTES, France, May 11, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been invited to provide an update on its R&D programs in immuno-oncology at two dedicated international conferences in May and June. Immuno-oncology platform - BI 765063 (OSE-172, . OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. NANTES, France, May 03, 2022 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and OSE . OSE Immunotherapeutics Reports 2021 Financial Results: Major ... - Benzinga OSE Immunotherapeutics Announces Four Poster Presentations of ... OSE Immunotherapeutics Presented New Translational Data on ... - Yahoo! OSE Immunotherapeutics to Host an "Immuno-Oncology R&D Day" On October ... OSE Immunotherapeutics Presented New Translational Data on ... - Yahoo! OSE Immunotherapeutics To Present at 'Immuno-Oncology Summit Europe ... thomas.guillot@ose-immuno.com +33 6 07 38 04 31 Media : FP2COM Florence Portejoie fportejoie@fp2com.fr +33 6 07 76 82 83 Déclarations prospectives Ce communiqué contient de manière implicite ou expresse des informations et déclarations pouvant être considérées comme prospectives
Bastien Lejeune Et Charlotte D'ornellas,
Maison Bixente Lizarazu Guéthary,
Articles A